We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Human Genome Sciences Announces License Agreement with Amgen
News

Human Genome Sciences Announces License Agreement with Amgen

Human Genome Sciences Announces License Agreement with Amgen
News

Human Genome Sciences Announces License Agreement with Amgen

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Human Genome Sciences Announces License Agreement with Amgen"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Human Genome Sciences, Inc. has announced a license agreement with Amgen under which Amgen has acquired exclusive worldwide rights to develop and commercialize therapeutic biological products for human use based on a human gene discovered by Human Genome Sciences that may have potential applications in autoimmune diseases, immune deficiencies or suppression, and cancer.

In addition, Amgen has acquired non-exclusive worldwide rights for the development and commercialization of diagnostic products for human use based on the same gene.

According to the terms of the agreement, Human Genome Sciences will receive from Amgen an upfront payment and certain annual fees, as well as development milestone payments and royalties on annual net sales for therapeutic and diagnostic products developed and commercialized using such rights.

H. Thomas Watkins, President and Chief Executive Officer, Human Genome Sciences, said, "We are pleased to enter into this agreement with Amgen."

"This agreement is one more step in our monetization of Human Genome Sciences assets and in providing access to our technology to those companies who share our goal of developing gene-based therapeutic and diagnostic products for use in the treatment of serious diseases."

Advertisement